Hepatitis C Articles (HCV)
Back
	Point-of-care HCV RNA testing with peer-led and nurse-based support to enhance HCV treatment among people with recent injecting drug use at a community-led needle and syringe program: the TEMPO pilot study - see study results below       HCV Models of Care - Point Of Care Finger Stick Rapid HCV Testing Outside USA Because These Technologies like GeneXPert are Not Yet approved Here in USA But Are In Use In Australia & Europe AASLD: Rapid Hepatitis C Treatment Initiation in Young People Who Inject Drugs: Final Results from the HCV-Seek, Test & Rapid Treatment (HCV-ST&RT) Randomized Pilot Clinical Trial - in NYC (11/15/21)   AASLD: HCV-RNA VIRAL LOAD FINGERSTICK ASSAY AS A SIMPLIFIED STRATEGY FOR SCREENING AND LINKAGE TO CARE OF PEOPLE WHO USE DRUGS ATTENDING ITALIAN ADDICTION TREATMENT CENTRES: A PILOT PROJECT - (11/15/21)   AASLD: A COMMUNITY-BASED TRIAL OF HEPATITIS C TREATMENT AT POINT OF DIAGNOSIS FOR MARGINALIZED POPULATIONS: PRELIMINARY RESULTS FROM THE NO ONE WAITS (NOW) STUDY - (11/16/21)   AASLD: The impact of the COVID-2019 pandemic on HCV testing and treatment in the United States - (11/17/21)   AASLD: THE IMPACT OF THE COVID-19 PANDEMIC ON HCV TESTING AND TREATMENT IN THE UNITED STATES - Between February 2020 and March 2020, the predicted number of tests dropped significantly by 33% but started to improve; Treatment Initiation dropped by 31% - (11/12/21)   AASLD: HEPATITIS C TREATMENT IN THE UNITED STATES, 2014-2020 numbers of treated is "below that needed to ensure elimination in USA by 2030, increased screening needed, remove all rstrictions" - (11/17/21)   AASLD: Global Status Update on the HCV Prevalence and Cascade of Care Entering 2020 - (11/17/21)   AASLD: Global status update on the HCV prevalence and cascade of care entering 2020 - lack of progress - Mark Mascolini - (11/15/21)   AASLD: Excellent Efficacy and Safety of Sofosbuvir, Glecaprevir, Pibrentasvir and Ribavirin for Retreatment of Chronic Hepatitis C after Sofosbuvir, Velpatasvir and Voxilaprevir Failure - (11/16/21)   AASLD: HBV and HCV are Each Associated with Adverse Pregnancy Complications: a 7-year Nationwide Inpatient Sample Study - (11/13/21)   AASLD: CIRRHOSIS IS ASSOCIATED WITH SIGNIFICANT ADVERSE PREGNANCY COMPLICATIONS: A 7-YEAR NATIONWIDE INPATIENT SAMPLE STUDY - (11/12/21)   AASLD: USE OF SOFOSBUVIR/VELPATASVIR IN TEST AND TREAT STRATEGY IN FRANCE: SNAPSHOT ANALYSIS OF PROSPECTIVE COHORT STUDY HELIOS 3 - (11/12/21)   AASLD: SUCCESSFUL IMPLEMENTATION OF UNIVERSAL HCV SCREENING AT A SAFETY-NET HOSPITAL'S EMERGENCY DEPARTMENT DURING THE COVID-19 PANDEMIC - 6% Overall HCV prevalence: 13% in baby boomers; 4% in nonBBs, overall chronic infection 2.5%; low linkage to care - (11/12/21)   ---------------------------   Point-of-care HCV RNA testing with peer-led and nurse-based support to enhance HCV treatment among people with recent injecting drug use at a community-led needle and syringe program: the TEMPO pilot study   INSHU 2021 Oct 12-15           View Older Articles   Back to Top   www.natap.org